Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Krankenhaus Landshut Achdorf | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Local abnormal ventricular activity (LAVA) is composed of high-frequency, mainly low voltage signals that represent near-field signals from slow-conducting tissue and thus potential VT isthmuses. The identification of LAVA potentials and their modification have usually been a complimentary component of the substrate-based modification of scar related ventricular arrhtyhmias. With better identification through technical solutions and improved algorithms, LAVA modification may be feasible for treatment in therapy refractory VT.
As of 2019 we started LAVA modification only in a subset of patients with therapy refractory ventricular tachycardia. The cohort icludes 55% patient with ischemic cardiomyopathy and 45% with dilated cardiomyopathy. 80% are ICD recipients. These patients were now retrospectively analysed in depth. The endpoint is time to relapse of ventricular tachycardia or ICD shock or death due to malignant arrhythmia. We evaluated all patients we treated accordingly from March 2019 through October 2020. No patient was excluded.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cardiac ablation therapy | Procedure | In a subset of patients with known therapy refractory arrhythmia sole LAVA modification is fashioned |
|
| Measure | Description | Time Frame |
|---|---|---|
| VT | occurrence/documentation of ventricular arrhythmia in participant after substrate modification during follow-up period (either Holter ECG or defibrillator interogation or ILR/ICM or electrophysiology study) | 12 months |
| appropriate therapy delivered by defibrillator (ICD) | appropriate therapy (shock, ATP) delivered by ICD in participants during follow-up period | 12 months |
| death | patient succumbed due to malignant ventricular arrhythmia or therapy | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| death any cause | death any cause during observation period | 36 months |
Not provided
Inclusion Criteria:
therapy refractory ventricular arrhythmia
Exclusion Criteria:
none
Not provided
Not provided
Not provided
all consecutive patients undergone LAVA modification alone for treatment of therapy refractory ventricular arrhythmia
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hendrik Bonnemeier, PhD | University of Kiel - Medical Faculty | Study Director |
| Stefan Borov, MD | University of Kiel - Medical Faculty | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Krankenhaus Landshut Achdorf | Landshut | Bavaria | 84036 | Germany |
Spreadsheet with characteristics (e.g.; procedure time, etc)
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017180 | Tachycardia, Ventricular |
| ID | Term |
|---|---|
| D013610 | Tachycardia |
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D000075224 |
| Cardiac Conduction System Disease |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |